IncRNA MVIH correlates with disease features, predicts treatment response and survival in pediatric acute myeloid leukemia

Xue, Hongjuan; Gao, Haili; Xia, Hong; Li, Shaofei; Li, Na; Gao, Chao; Duan, Yuwen; Ren, Yanfei; Zhang, Henglu; Liu, Jingzheng; Gao, Wei

doi:10.1002/jcla.23739

Cited by 3 publications

(3 citation statements)

References 14 publications

(28 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Risk stratification of AML from NCCN guidelines can help us judge the prognosis of patients and guide the treatment. However, the therapeutic effects of patients in the same risk stratification vary markedly, indicating the underlying heterogeneity within the same risk stratification group 26,27 . Our result showed that patients with high expression of AC026150.8 had a shorter OS in both favorable and intermediate risk groups, but the difference was not statistically significant.…”

Section: Discussionmentioning

confidence: 61%

“…However, the therapeutic effects of patients in the same risk stratification vary markedly, indicating the underlying heterogeneity within the same risk stratification group. 26,27 Our result showed that patients with high expression of AC026150.8 had a shorter OS in both favorable and intermediate risk groups, but the difference was not statistically significant. This may be caused by the small sample size after patient stratification.…”

Section: Ac0261508 Interacts With Alternative Splicing-related Proteinsmentioning

confidence: 64%

See 1 more Smart Citation

A novel upregulated LncRNA‐AC026150.8 promotes chemo‐resistance and predicts poor prognosis in acute myeloid leukemia

Zhang

Zhao

et al. 2021

Cancer Medicine

View full text Add to dashboard Cite

Background AML is a common hematological malignancy with poor prognosis, the pathogenesis is still unclear. lncRNA takes part in occurrence and development of AML. This research aims to explore new differentially expressed lncRNAs and their effects on AML. Methods Database‐based bioinformatics analysis was performed to screen differentially expressed lncRNA in AML, real‐time PCR was used to analyze gene expression. Kaplan–Meier survival analysis was performed to determine prognostic effect of AC026150.8 in AML. The cell drug resistance experiment was performed to test effect of AC026150.8 on chemo‐resistance of AML cells. Catrapid online software and RNA pull‐down, mass spectrometry, western‐blot were used to predict and verify the combination of AC026150.8 and RNA splicing factors. Results AC026150.8 was upregulated in AML patients and related to poor prognosis. High leukocyte counts, FAB classification, MLL‐AF9 expression and NPM1 mutations were associated with high AC026150.8 expression. Upregulated of AC026150.8 increased the drug resistance of AML cells. AC026150.8 could be combined with splicing factor PCBP1. Conclusions For the first time, our study found that the upregulated AC026150.8 in AML is related to poor prognosis, overexpression of AC026150.8 could increase drug resistance of AML cells, and confirmed its scaffolding effect in combination with splicing factors. It is necessary to further study AC026150.8 and its downstream target genes to clarify the mechanism of AC026150.8 in AML.

show abstract

Section: Discussionmentioning

confidence: 61%

Section: Ac0261508 Interacts With Alternative Splicing-related Proteinsmentioning

confidence: 64%

A novel upregulated LncRNA‐AC026150.8 promotes chemo‐resistance and predicts poor prognosis in acute myeloid leukemia

Zhang

Zhao

et al. 2021

Cancer Medicine

View full text Add to dashboard Cite

show abstract

“…The risk factors associated with the prognosis of childhood ALL were as follows: (i) aged ≤1 year or >10 years; (ii) white blood cell (WBC) ≥150 ×10 9 /L at diagnosis; (iii) diagnosed as central nervous system leukemia or testicular leukemia; (iv) immunophenotype with T cell acute lymphoblastic leukemia; (v) adverse cytogenetic characteristics, such as t(9;22) (BCR-ABL) and t(4;11) (MLL-AF4); (vi) PPR with prednisone response; (vii) M3 of bone marrow response at day 15; (viii) M2 or M3 of bone marrow response at day 33; (ix) minimal residual disease (MRD) >1 ×10 −4 at day 33. Patients were stratified into three risk groups: (1) low risk: no risk factors related to the prognosis of childhood ALL; (2) intermediate risk: had any one or more of the following conditions: (i) aged≤1 year or >10 years; (ii) WBC ≥150 ×10 9 /L; (iii) confirmed as central nervous system leukemia or testicular leukemia; (iv) had immunophenotype of T cell ALL; (v) t(1;9) (q23; p13)/ E2A-PBX1 positive; (vi) confirmed as low risk at diagnosis and M3 of bone marrow response at day 15; and (vii) MRD within 1 ×10 −4 - 1 ×10 −2 ; at day 33; (3) high risk: had any one or more of the following conditions: (i) t(9;22) (q34; q11.2)/ BCR-ABL1 positive; (ii) t(4;11) (q21; q23) MLL-AF4 or other MLL genes positive; (iii) PPR of prednisone response; (iv) confirmed as low risk at diagnosis and M3 of bone marrow response at day 15; (v) M2 or M3 of bone marrow response at day 33; and (vi) MRD >1 ×10 −2 at day 33 21,22…”

Section: Methodsmentioning

confidence: 99%

Polo-like Kinase 4: the Variation During Therapy and its Relation to Treatment Response and Prognostic Risk Stratification in Childhood Acute Lymphoblastic Leukemia Patients

Xu¹,

Zhao

2022

Journal of Pediatric Hematology/Oncology

View full text Add to dashboard Cite

Polo-like kinase 4 (PLK4) plays an essential role in the tumorigenesis of some blood malignancies; consequently, we hypothesized that PLK4 might serve as a potential biomarker in childhood acute lymphoblastic leukemia (ALL) patients. Therefore, this study investigated the expression of PLK4 and its clinical relevance in childhood ALL patients. Bone marrow specimens were collected from 95 childhood ALL patients and 20 primary immune thrombocytopenia patients (as controls), and their PLK4 expression (reverse transcription-quantitative polymerase chain reaction) was measured after enrollment. Besides, the PLK4 expression in childhood ALL patients was also determined at day 15 after the initiation of induction therapy (D15). PLK4 was increased in childhood ALL patients compared with controls (2.830 (interquartile range (IQR): 1.890-3.660) versus 0.976 (IQR: 0.670-1.288), P≤0.001). PLK4 at diagnosis was elevated in T cell acute lymphoblastic leukemia patients than in B cell acute lymphoblastic leukemia patients (P=0.027). Besides, PLK4 at diagnosis was positively linked with the Chinese Medical Association risk stratification (P=0.016), but not with prednisone response (P=0.077) or bone marrow response (P=0.083). In addition, PLK4 was decreased at D15 after treatment compared with at diagnosis (P≤0.001). Interestingly, PLK4 at D15 (P=0.033) was elevated in T cell acute lymphoblastic leukemia patients than in B cell acute lymphoblastic leukemia patients. Furthermore, increased PLK4 at D15 was associated with poor prednisone response (P=0.018), poor bone marrow response (P=0.034), and increased the Chinese Medical Association risk stratification (P=0.015). In terms of prognosis, high PLK4 was associated with shorter event-free survival (P=0.020), whereas it was not related to the overall survival (P=0.135). In conclusion, PLK4 has the potential as a biomarker for treatment response and prognostic risk stratification of childhood ALL patients.

show abstract

Long noncoding RNAs as regulators of pediatric acute myeloid leukemia

Neyazi

Heckl

et al. 2022

Mol Cell Pediatr

View full text Add to dashboard Cite

Long noncoding RNAs (lncRNAs) are increasingly emerging as regulators across human development and disease, and many have been described in the context of hematopoiesis and leukemogenesis. These studies have yielded new molecular insights into the contribution of lncRNAs to AML development and revealed connections between lncRNA expression and clinical parameters in AML patients. In this mini review, we illustrate the versatile functions of lncRNAs in AML, with a focus on pediatric AML, and present examples that may serve as future therapeutic targets or predictive factors.

show abstract

IncRNA MVIH correlates with disease features, predicts treatment response and survival in pediatric acute myeloid leukemia

Abstract: This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Cited by 3 publications

References 14 publications

A novel upregulated LncRNA‐AC026150.8 promotes chemo‐resistance and predicts poor prognosis in acute myeloid leukemia

A novel upregulated LncRNA‐AC026150.8 promotes chemo‐resistance and predicts poor prognosis in acute myeloid leukemia

Polo-like Kinase 4: the Variation During Therapy and its Relation to Treatment Response and Prognostic Risk Stratification in Childhood Acute Lymphoblastic Leukemia Patients

Long noncoding RNAs as regulators of pediatric acute myeloid leukemia

Contact Info

Product

Resources

About